CUG 252
Alternative Names: CUG-252Latest Information Update: 07 Mar 2025
At a glance
- Originator Cugene
- Class Anti-inflammatories; Antirheumatics; Peptides; Skin disorder therapies
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis; Inflammatory bowel diseases; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 07 Mar 2025 CUG 252 is still in a phase I trial for Systemic lupus erythematosus, Atopic dermatitis, Inflammatory bowel disease, Rheumatoid arthritis in USA (SC) (NCT05328557)
- 28 Dec 2024 No recent reports of development identified for phase-I development in Atopic-dermatitis(In volunteers) in USA (SC, Injection)
- 28 Dec 2024 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers) in USA (SC, Injection)